Healthcare Industry News: cIAI
News Release - March 24, 2009
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial PneumoniaIndication Offers New Option for Adult Patients Suffering From Community-Acquired Bacterial Pneumonia
COLLEGEVILLE, Pa., March 24 (Healthcare Sales & Marketing Network) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced today that the U.S. Food and Drug Administration (FDA) approved TYGACILŪ (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens. TYGACIL was first approved by the FDA in 2005 for the treatment of complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) caused by susceptible strains of indicated pathogens in adults.
"The approval of this new indication is timely. Antibiotic resistance continues to grow and new antimicrobials are needed," says Joseph Camardo, M.D., Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals. "The approval of TYGACIL for CABP is an important milestone in Wyeth's commitment to exploring new treatment options in the anti-infective therapeutic area."
Thomas File, M.D., Chief of Infectious Disease Services for Summa Health System in Akron, Ohio, says, "CABP is a serious and potentially fatal respiratory disease that affects millions of Americans each year. The approval of TYGACIL for CABP means that physicians will have an additional option available to treat patients suffering from the disease."
CABP accounts for an estimated 4.5 million visits to physician offices, emergency departments, and outpatient clinics each year.
About the CABP Clinical Trials
The approval was based on results of two randomized, double-blind, active-controlled, multinational studies (Studies 308 and 313) that evaluated TYGACIL for the treatment of CABP in adults. The two studies (N=859) were conducted at 116 sites in 28 countries and evaluated the efficacy and safety of TYGACIL compared with levofloxacin in subjects hospitalized with CABP. Results showed that clinical cure rates of patients hospitalized with CABP were comparable for both TYGACIL and levofloxacin. Clinical cure rates in clinically evaluable patients were 90.6 percent for TYGACIL and 87.2 percent for levofloxacin in Study 308 and 88.9 percent for TYGACIL and 85.3 percent for levofloxacin in Study 313.
About Community-Acquired Bacterial Pneumonia
Community-acquired bacterial pneumonia, or CABP, is commonly defined as an acute infection of the pulmonary parenchyma (the functional part of the lungs) that is generally associated with at least some symptoms of acute infection, in a patient who has not been hospitalized or resided in a long-term care facility within 14 days of symptom onset. Symptoms of CABP include cough, fever, chills, fatigue, shortness of breath, and chest pain.
TYGACIL is indicated for the treatment of adults with:
Complicated skin and skin structure infections (cSSSI) caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis.
Complicated intra-abdominal infections (cIAI) caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros.
Community-acquired bacterial pneumonia (CABP) caused by Streptococcus pneumoniae (penicillin-susceptible isolates), including cases with concurrent bacteremia, Haemophilus influenzae (beta-lactamase negative isolates), and Legionella pneumophila.
In vitro activity of TYGACIL
TYGACIL, the first glycylcycline IV antibiotic has an expanded broad spectrum of in vitro activity against many gram positives, gram negatives, anaerobes, methicillin-resistant and -susceptible Staphylococcus aureus (MRSA and MSSA), and vancomycin-resistant enterococci (VRE). TYGACIL is unaffected by extended-spectrum beta-lactamases (ESBLs).
With this approval, the in vitro profile of TYGACIL has now been expanded to include: Haemophilus influenzae (ampicillin-resistant) and Haemophilus parainfluenzae. The clinical significance of in vitro activity is unknown.
TYGACIL can be used as an empiric monotherapy to treat a variety of cIAI and cSSSI, both hospital- and community-acquired, including complicated appendicitis, intra-abdominal abscesses, infected burns, deep soft-tissue infections, and infected ulcers.
TYGACIL provides clinicians with an expanded broad-spectrum antibiotic option that can be used at the onset of treatment when the specific bacteria present are not yet known. When culture and susceptibility information are available, they should be considered in modifying antibacterial therapy. In addition, TYGACIL does not require dosage adjustment in patients with impaired renal function, and is conveniently dosed every 12 hours.
Important Safety Information
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria
- Anaphylaxis/anaphylactoid reactions have been reported with nearly all antibacterial agents, including tigecycline, and may be life-threatening
- TYGACIL is contraindicated in patients with known hypersensitivity to tigecycline
- TYGACIL should be administered with caution in patients with known hypersensitivity to tetracycline class antibiotics
- TYGACIL is structurally similar to tetracycline-class antibiotics and may have similar adverse effects. Such effects may include: photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, and hyperphosphatemia). As with tetracyclines, pancreatitis has been reported with the use of TYGACIL
- The safety and efficacy of TYGACIL in patients with hospital-acquired pneumonia have not been established
- In clinical trials, the most common treatment-emergent adverse events in patients treated with TYGACIL were nausea (26%) and vomiting (18%)
- TYGACIL may cause fetal harm when administered to a pregnant woman
- The safety and effectiveness of TYGACIL in patients below age 18 and lactating women have not been established
- Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including TYGACIL, and may range in severity from mild diarrhea to fatal colitis
- Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective
- The use of TYGACIL during tooth development may cause permanent discoloration of the teeth. TYGACIL should not be used during tooth development unless other drugs are not likely to be effective or are contraindicated
- Prothrombin time or other suitable anticoagulant test should be monitored if TYGACIL is administered with warfarin
- Monotherapy should be used with caution in patients with clinically apparent intestinal perforation
- Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications. Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening hepatic function. Adverse events may occur after the drug has been discontinued
- In patients with severe hepatic impairment (Child Pugh C), the initial dose of TYGACIL should be 100 mg followed by 25 mg every 12 hours. Patients should be treated with caution and monitored for treatment response
- The following drugs should not be administered simultaneously through the same Y-site as TYGACIL: amphotericin B and diazepam
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.